Dimensional Fund Advisors
SABS icon

Dimensional Fund Advisors’s SAB Biotherapeutics SABS Stock Holding History

Dimensional Fund Advisors’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-15,781
Closed -$31.7K – 3307
2025
Q3 		$31.7K Buy
+15,781
New +$35.7K ﹤0.01% 3257

Other funds holding SABS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Dimensional Fund Advisors's SABS Position: Q4 2025 in Review

Dimensional Fund Advisors sold out of SAB Biotherapeutics (SABS) in Q4 2025, closing a stake of 15,781 shares — an estimated $31.7K sold.

Dimensional Fund Advisors first reported a position in SABS in Q3 2025 and held it in 1 quarter. The position peaked at $31.7K in Q3 2025. 48 funds tracked by Wall St. Rank hold SABS as of Q4 2025.

  • Dimensional Fund Advisors reported no remaining SAB Biotherapeutics position as of Q4 2025 after selling out during the quarter.
  • Dimensional Fund Advisors sold 15,781 SAB Biotherapeutics shares in Q4 2025, an estimated $31.7K.
  • Dimensional Fund Advisors first reported a position in SAB Biotherapeutics in Q3 2025 and held it in 1 quarter.
  • Dimensional Fund Advisors's SAB Biotherapeutics position peaked at $31.7K in Q3 2025.
  • 48 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q4 2025.

Based on Dimensional Fund Advisors's 13F filing for Q4 2025, filed 12 Feb 2026.